Industry news that matters to you.  Learn more

Archives for November 2014

Enterome Enters into a Microbiome-Based Development Collaboration with AbbVie in Crohn’s Disease

ENTEROME Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a thorough understanding of the gut microbiome, recently announced that it has entered into a collaborative development agreement with AbbVie. The alliance is anchored around Enterome’s proprietary metagenomic biomarker portfolio and technologies that may enable the development of novel diagnostic products to support personalized therapies and the development of new drugs in microbiome-related diseases.

SomaLogic Launches SOMAmer Discovery Service, “SOMAmer Challenge”

SomaLogic recently announced the launch of a new proteomics service offering aimed at providing its breakthrough protein-binding SOMAmer® reagents to the scientific community based on their specific needs in wide variety of different research uses. The SOMAmer Discovery Service team at SomaLogic will work closely with SomaLogic customers to develop and license “fit-for-purpose” SOMAmer reagents that strongly bind the customers’ proteins of interest, and function correctly in the particular assays they are performing with the reagents.

QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced it has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.

World Fusion and Lumenogix Announce Global Strategic Partnership

World Fusion Co., LTD and Lumenogix Inc. recently announced a strategic partnership to provide a complete solution for the pharmaceutical industry that integrates the World Fusion Life Sciences Knowledge Bank (LSKB) for accelerating drug discovery with the Lumenogix Bioinformatics-in-a-Box™ for analyzing Next Generation Sequencing (NGS) data.

Strand Life Sciences to Demonstrate New StrandOmics Features at AMP 2014 Annual Meeting

Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company’s variant interpretation and reporting software, StrandOmics at the Association For Molecular Pathologist (AMP) 2014 Annual Meeting to be held from November 12th to 15th in National Harbor, Maryland. The 20th anniversary meeting’s theme is “Realizing the Dream of Precision Medicine,” with a special address by Dr. Francis Collins, Director of the National Institute of Health. At AMP, Strand will host a workshop on the innovative developments and application of its StrandOmics software, plus new expansion efforts in Personalized Medicine.